[Influence of hormone substitution therapy on postmenopausal uterus].

In: Nuklearmedizin. Nuclear medicine · 1997 · vol. 36(8) , pp. 295–7 · PMID:17068882 · W2376883450
article OA: closed CC0
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-07, 2026-07-15

Hormone replacement therapy in postmenopausal women may explain focal increased activity in the pelvis on bone scintigraphy by causing a premenstrual stage in the uterus.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

In a 58-year-old postmenopausal woman blood flow and blood pool images of bone scintigraphy showed a focus of increased activity in the right pelvic region. Computed tomography and ultrasound exhibited no abnormalities in the abdomen; especially the uterus and ovaries were normal. Careful anamnestic evaluation revealed that the patient received a long-term peroral estrogen/gestagen replacement therapy for the prevention of osteoporosis, but did not have menstruation-like bleedings for the last twelve months of therapy. At time of admission, the patient was on day 25 of hormone replacement therapy, and the uterus was, therefore, in a premenstrual stage. Hence, despite cessation of bleedings in postmenopausal women, one should think of hormone replacement therapy as an explanation for vascular pelvic tumors seen by the first two phases of bone scintigraphy, before further diagnostic steps are undertaken.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK